Eli Lilly recently spoke out against proposed tariffs on pharmaceuticals, warning they could increase drug costs and restrict patient access.
The drugmaker said it has invested more than $50 billion in U.S. manufacturing since 2020, including 10 projects aimed at supplying the domestic market entirely from within the country, according to an Aug. 14 news release from the company.
President Donald Trump recently floated a tariff on pharmaceuticals as high as 250% as part of a greater push to bring more drug manufacturing to the U.S.
Eli Lilly also said although it supports efforts to make drug pricing more equitable globally, it calls for reforms that address systemic issues in the U.S. market — such as complex pricing structures, insurance cost sharings and misuse of programs including 340B — without relying on tariffs.
The drugmaker is working with governments abroad, including reaching an agreement with the U.K. to raise the price of Mounjaro, as part of efforts to raise drug prices in other countries and push for lower prices in the U.S., the release said.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
